X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Leap intends to use the net proceeds from the financing to fund the continued development of its lead monoclonal antibody program, DKN-01 for the treatment of Colorectal Cancer.
Lead Product(s): Sirexatamab,Fluorouracil,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: DKN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Leap Therapeutics
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 11, 2024
Details:
The collaboration aims to support the clinical development of GS-6791 (NX-0479), a potent, selective, oral IRAK4 degrader that has potential applications in the treatment of rheumatoid arthritis and other inflammatory diseases
Lead Product(s): NX-0479
Therapeutic Area: Immunology Product Name: GS-6791
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Nurix Therapeutics
Deal Size: $1,903.5 million Upfront Cash: $45.0 million
Deal Type: Collaboration April 02, 2024
Details:
Through the license agreement, Gilead will leverage an exclusive global license to develop and commercialize XTX301, Xilio’s tumor-activated IL-12. Currently, it is being evaluated in Phase I clinical trial studies for the treatment of Neoplasms.
Lead Product(s): XTX301
Therapeutic Area: Oncology Product Name: XTX301
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Xilio Therapeutics
Deal Size: $647.5 million Upfront Cash: $43.5 million
Deal Type: Licensing Agreement March 28, 2024
Details:
Vemlidy (tenofovir alafenamide) is a nucleoside analog reverse transcriptase inhibitor. It is approved for treatment for chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.
Lead Product(s): Tenofovir Alafenamide
Therapeutic Area: Infections and Infectious Diseases Product Name: Vemlidy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
Through the acquisition, Gilead expand its liver portfolio with CymaBay’s investigational, MBX-8025 (seladelpar), an oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist for the treatment of primary biliary cholangitis (PBC) including pruritus.
Lead Product(s): Seladelpar
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MBX-8025
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: CymaBay Therapeutics
Deal Size: $4,300.0 million Upfront Cash: $4,300.0 million
Deal Type: Acquisition March 22, 2024
Details:
The collaboration aims to use Merus’ proprietary Triclonics® platform along with Gilead’s oncology expertise to research and develop multiple, separate preclinical research programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Merus
Deal Size: $1,581.0 million Upfront Cash: $56.0 million
Deal Type: Collaboration March 06, 2024
Details:
MK-8591 (islatravir) is a non-nucleoside reverse transcriptase translocation inhibitor, which is being investigated in phase 2 for HIV-1 infection, in combination with lenacapavir.
Lead Product(s): Islatravir,Lenacapavir
Therapeutic Area: Infections and Infectious Diseases Product Name: MK-8591
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a USFDA approved fixed dose combination. It is being evaluated for the treatment of HIV and Hepatitis B.
Lead Product(s): Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area: Infections and Infectious Diseases Product Name: Biktarvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
GS-9883 (bictegravir), an HIV type 1 integrase inhibitor in combination with GS-6207 (lenacapavir), a structural capsid protein inhibitor is being evaluated for the treatment of HIV-1-infection.
Lead Product(s): Bictegravir,Lenacapavir
Therapeutic Area: Infections and Infectious Diseases Product Name: GS-9883
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
The financing aims to support the company in the clinical development of Trodelvy (sacituzumab govitecan), rop-2 directed antibody-drug conjugate. It is being evaluated for the treatment of Non-Small Cell Lung Cancer.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Abingworth
Deal Size: $210.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 29, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
